Navigation Links
Tolerx Announces Amendment to Phase 3 DEFEND Protocol
Date:8/11/2009

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced changes to the protocol for its Phase 3 clinical trial DEFEND, which is testing the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

The DEFEND (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) protocol amendment includes two key changes to the study: expansion of the eligible patient age range from 18-35 years to 12-45 years, and the shortening of the infusion time for each administration of otelixizumab from 2 hours to 30 minutes. Both of these enhancements are supported by clinical data derived from Tolerx's ongoing Phase 2 study called TTEDD.

"From a clinical perspective, I believe this amendment significantly improves the protocol for the DEFEND trial," said Peter A. Gottlieb, MD, Associate Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado at Denver, and a principal investigator in the DEFEND study. "Most notably, through the expansion of the patient age range to include adolescents, Tolerx is widening the options available to physicians interested in providing new investigational treatment options to this important and growing adolescent patient population."

Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx, also commented on the news: "We are pleased with this amendment on multiple levels and are hopeful that both the expansion of the target population and the more convenient dosing regimen will further expand the enthusiasm for this trial in the diabetes community. Our commitment to type 1 diabetes patients is evidenced in our efforts to develop a short, conven
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Nitto Avecia, a ... its increased capacity and production capability to serve ... variety and service fulfillment continues to drive Nitto ... process throughput capacities. , In Fall ... downstream process equipment at its Milford, MA facility, ...
(Date:4/30/2015)... SEATTLE , April 30, 2015  The Paul ... Allen Distinguished Investigator (ADI) grants to six groups of ... the most challenging roadblocks in neuroscience: growing mature human ... at a total of $7.5 million over three years.  ... Investigators and their research is especially significant because the ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... R&D services provider, today announced that its board of ... April 29, 2015, from a consortium (the "Consortium") led ... chairman and chief executive officer of the Company, and ... transaction (the "Transaction") involving the acquisition of all outstanding ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... lab that studies learning technologies with the University of Wisconsin and ... evening at the World Futurist Society meeting . The futurists ... at the Academic Advanced Distributed Learning Co-Lab , Brown will ... looking to video games as a teaching tool. Read more. ...
... Wisconsin Governor Jim Doyle and former Governor Tommy Thompson ... advantages of electronic health records, however, Doyle and Thompson ... two-year state budget includes $10 million in grants and ... health records, a move that could help harness the ...
... First Dolly, now human embryos. , ,This weeks announcement out ... who cloned Dolly the sheep, has been granted a license ... to spark fresh hopes among disease sufferers, scientists and advocacy ... amyotrophic lateral sclerosis (ALS). , ,These diseases could be addressed ...
Cached Biology Technology:Tech Digest: Futurists on learning; Sonic Foundry; Accu Tech; Fiserv 2Electronic health records can save lives and improve medical care 2Electronic health records can save lives and improve medical care 3Human cloning plans get blessing from British government 2Human cloning plans get blessing from British government 3
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... may point to a treatment for the debilitating condition ... in the Feb. 8 issue of Nature, researchers from ... naturally occurring chemicals found in the brain that are ... helped trigger a dramatic improvement in mice with a condition ...
... team of scientists has discovered that the ubiquitous bacteria ... in the human digestive system since modern man migrated ... online today (7 February) by the journal Nature, not ... but also offers a new way to study the ...
... why, in some people, the immune system turns against ... leading to autoimmune disease. Now, researchers at the National ... Musculoskeletal and Skin Diseases (NIAMS), in collaboration with the ... into one likely factor: the early development of immune ...
Cached Biology News:Enhancing activity of marijuana-like chemicals in brain helps treat 2Enhancing activity of marijuana-like chemicals in brain helps treat 3Prehistoric origins of stomach ulcers uncovered 2Scientists learn the origin of rogue B cells 2
... ChromaDoc-It features a 4.1 mega pixel ... capturing brilliant TLC color images., The ... shortwave and longwave UV tubes positioned on ... illumination for fluorescence studies , Interior ...
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
... thermoactive designer enzyme that enables RT-PCR ... PCR enzyme allows reverse transcription and ... elevated temperatures (65C), which helps to ... and results in highly stringent, accurate ...
Request Info...
Biology Products: